The exome sequencing identified the mutation in YARS2 encoding the mitochondrial tyrosyl-tRNA synthetase as a nuclear modifier for the phenotypic manifestation of Leber's hereditary optic neuropathy-associated mitochondrial DNA mutation

• Published in: Human molecular genetics Vol. 25; no. 3; pp. 584 - 596
• Main Authors: Jiang, Pingping, Jin, Xiaofen, Peng, Yanyan, Wang, Meng, Liu, Hao, Liu, Xiaoling, Zhang, Zengjun, Ji, Yanchun, Zhang, Juanjuan, Liang, Min, Zhao, Fuxin, Sun, Yan-Hong, Zhang, Minglian, Zhou, Xiangtian, Chen, Ye, Mo, Jun Qin, Huang, Taosheng, Qu, Jia, Guan, Min-Xin
• Format: Journal Article
• Language: English
• Published: England 01.02.2016
• Subjects: Alleles; Base Sequence; Case-Control Studies; Cell Line; Cyclooxygenase 2 - genetics; Cyclooxygenase 2 - metabolism; DNA, Mitochondrial - genetics; DNA, Mitochondrial - metabolism; Electron Transport Complex I - genetics; Electron Transport Complex I - metabolism; Electron Transport Complex IV - genetics; Electron Transport Complex IV - metabolism; Exome; Gene Expression Regulation; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Mitochondria - enzymology; Mitochondria - genetics; Mitochondria - pathology; Mitochondrial Proteins - chemistry; Mitochondrial Proteins - genetics; Mitochondrial Proteins - metabolism; Models, Molecular; Molecular Sequence Data; Mutation; NADH Dehydrogenase - genetics; NADH Dehydrogenase - metabolism; Neurons - enzymology; Neurons - pathology; Optic Atrophy, Hereditary, Leber - enzymology; Optic Atrophy, Hereditary, Leber - genetics; Optic Atrophy, Hereditary, Leber - pathology; Pedigree; Phenotype; Tyrosine-tRNA Ligase - chemistry; Tyrosine-tRNA Ligase - genetics; Tyrosine-tRNA Ligase - metabolism
• DOI: 10.1093/hmg/ddv498
• ISSN: 0964-6906

Leber's hereditary optic neuropathy (LHON) is the most common mitochondrial disorder. Nuclear modifier genes are proposed to modify the phenotypic expression of LHON-associated mitochondrial DNA (mtDNA) mutations. By using an exome sequencing approach, we identified a LHON susceptibility allele (c.572G>T, p.191Gly>Val) in YARS2 gene encoding mitochondrial tyrosyl-tRNA synthetase, which interacts with m.11778G>A mutation to cause visual failure. We performed functional assays by using lymphoblastoid cell lines derived from members of Chinese families (asymptomatic individuals carrying m.11778G>A mutation, or both m.11778G>A and heterozygous p.191Gly>Val mutations and symptomatic subjects harboring m.11778G>A and homozygous p.191Gly>Val mutations) and controls lacking these mutations. The 191Gly>Val mutation reduced the YARS2 protein level in the mutant cells. The aminoacylated efficiency and steady-state level of tRNA(Tyr) were markedly decreased in the cell lines derived from patients both carrying homozygous YARS2 p.191Gly>Val and m.11778G>A mutations. The failure in tRNA(Tyr) metabolism impaired mitochondrial translation, especially for polypeptides with high content of tyrosine codon such as ND4, ND5, ND6 and COX2 in cells lines carrying homozygous YARS2 p.191Gly>Val and m.11778G>A mutations. The YARS2 p.191Gly>Val mutation worsened the respiratory phenotypes associated with m.11778G>A mutation, especially reducing activities of complexes I and IV. The respiratory deficiency altered the efficiency of mitochondrial ATP synthesis and increased the production of reactive oxygen species. Thus, mutated YARS2 aggravates mitochondrial dysfunctions associated with the m.11778G>A mutation, exceeding the threshold for the expression of blindness phenotype. Our findings provided new insights into the pathophysiology of LHON that were manifested by interaction between mtDNA mutation and mutated nuclear-modifier YARS2.